Douglas Jermasek - 11 Jul 2023 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Role: EVP of Corporate Strategy
Signature: /s/ Douglas Jermasek
Issuer symbol: UNCY
Transactions as of: 11 Jul 2023
Net transactions value: -$50,000
Form type: 4
Filing time: 13 Jul 2023, 19:33:54 UTC
Previous filing: 09 Mar 2023
Next filing: 30 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	UNCY	Common Stock	Options Exercise		+104,612	+149%		175,012	11 Jul 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	UNCY	Series A-1 Convertible Preferred Stock	Options Exercise	$50,000	-50	-100%	$1000.00^*	0	11 Jul 2023	Common Stock		$0.4900	Direct	F2
transaction	UNCY	Warrant (right to buy	Options Exercise		+79,252			79,252	11 Jul 2023	Series A-3 Convertible Preferred Stock	79,252	$0.5400	Direct	F1, F3
transaction	UNCY	Warrant (right to buy)	Options Exercise		+72,047			72,047	11 Jul 2023	Series A-4 Convertible Preferred Stock	72,047	$0.5900	Direct	F1, F4
transaction	UNCY	Warrant (right to buy)	Options Exercise		+115,275			115,275	11 Jul 2023	Series A-5 Convertible Preferred Stock	115,275	$0.7400	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.
F2	On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.
F3	The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.
F4	The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.
F5	The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.